Latest Financial Results News

National Australia Bank’s half year to March 2026 saw revenue climb 8.7% to $11.16 billion while net profit dropped 19.3%, hit by a $949 million accelerated software amortisation. Excluding this, cash earnings edged 2.3% higher, underpinned by strong business banking growth and cautious credit provisioning amid geopolitical uncertainty.

Bank of Queensland has finalised the sale of its equipment finance portfolio to Challenger for $3.62 billion, marking a pivotal step in its strategic transformation. The transaction sets the stage for potential shareholder returns through a buyback and special dividend, pending approvals.

Multistack International reversed a $1.68 million loss to report a $2.26 million profit in 2025, driven by $4 million in settlement and asset disposal income. The company plans to exit its loss-making Australian operations through a share disposal while exploring new business avenues.

ANZ Group Holdings Limited posted a 14% rise in cash profit for 1H26 to AUD 3.78 billion, driven by cost reductions and steady revenue, while declaring an 83-cent interim dividend with 75% franking.

InteliCare has locked in its largest-ever $8.8 million contract with mecwacare to deploy its AI-driven platform across 22 aged care homes, while appointing Angus Cameron as CEO to spearhead growth.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

DXN Limited posted a 47.5% revenue increase to $3.7 million in Q3 FY26, buoyed by a surge in modular data centre projects and a growing pipeline of 891 identified contracts. The company advanced its Asia-Pacific footprint through a JV in Indonesia and a Malaysian manufacturing push, while securing a $5.3 million Cable Landing Station contract in Latin America.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Adveritas Limited surged to $15.08 million ARR, up 91% year-on-year, powered by a new self-serve SME platform and AI-driven product enhancements.